health catalyst inc - HCAT

HCAT

Close Chg Chg %
1.16 0.01 0.86%

Closed Market

1.17

+0.01 (0.86%)

Volume: 411.06K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: health catalyst inc - HCAT

HCAT Key Data

Open

$1.12

Day Range

1.09 - 1.19

52 Week Range

1.04 - 5.06

Market Cap

$86.10M

Shares Outstanding

73.59M

Public Float

64.90M

Beta

1.82

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.53

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

885.75K

 

HCAT Performance

1 Week
 
6.36%
 
1 Month
 
-40.00%
 
3 Months
 
-48.68%
 
1 Year
 
-70.82%
 
5 Years
 
-97.57%
 

HCAT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About health catalyst inc - HCAT

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

HCAT At a Glance

Health Catalyst, Inc.
10897 South River Front Parkway
South Jordan, Utah 84095
Phone 1-801-708-6800 Revenue 311.14M
Industry Packaged Software Net Income -177,974,000.00
Sector Technology Services 2025 Sales Growth 1.485%
Fiscal Year-end 12 / 2026 Employees 1,200
View SEC Filings

HCAT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.537
Price to Book Ratio 0.70
Price to Cash Flow Ratio 228.52
Enterprise Value to EBITDA 24.761
Enterprise Value to Sales 0.78
Total Debt to Enterprise Value 0.706

HCAT Efficiency

Revenue/Employee 259,280.00
Income Per Employee -148,311.667
Receivables Turnover 5.236
Total Asset Turnover 0.457

HCAT Liquidity

Current Ratio 1.87
Quick Ratio 1.87
Cash Ratio 1.069

HCAT Profitability

Gross Margin 33.468
Operating Margin -13.082
Pretax Margin -56.971
Net Margin -57.201
Return on Assets -26.142
Return on Equity -58.258
Return on Total Capital -42.678
Return on Invested Capital -37.695

HCAT Capital Structure

Total Debt to Total Equity 69.671
Total Debt to Total Capital 41.062
Total Debt to Total Assets 34.068
Long-Term Debt to Equity 67.472
Long-Term Debt to Total Capital 39.766
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Health Catalyst Inc - HCAT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
276.24M 295.94M 306.58M 311.14M
Sales Growth
+14.18% +7.13% +3.60% +1.48%
Cost of Goods Sold (COGS) incl D&A
188.97M 203.34M 206.22M 207.00M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
51.53M 45.21M 41.43M 50.50M
Depreciation
14.33M 15.59M 12.80M 15.00M
Amortization of Intangibles
37.20M 29.62M 28.63M 35.50M
COGS Growth
+16.87% +7.60% +1.42% +0.38%
Gross Income
87.26M 92.60M 100.36M 104.13M
Gross Income Growth
+8.76% +6.12% +8.38% +3.76%
Gross Profit Margin
+31.59% +31.29% +32.74% +33.47%
2022 2023 2024 2025 5-year trend
SG&A Expense
210.15M 178.36M 155.12M 144.84M
Research & Development
69.22M 68.50M 56.80M 46.09M
Other SG&A
140.93M 109.86M 98.31M 98.75M
SGA Growth
+8.24% -15.13% -13.03% -6.63%
Other Operating Expense
- - - -
-
Unusual Expense
17.12M 41.14M 15.05M 120.15M
EBIT after Unusual Expense
(140.00M) (126.90M) (69.81M) (160.85M)
Non Operating Income/Expense
5.56M 16.39M 17.72M 7.85M
Non-Operating Interest Income
5.69M 16.39M 17.98M 7.54M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
7.24M 7.29M 17.09M 24.25M
Interest Expense Growth
-58.19% +0.66% +134.47% +41.95%
Gross Interest Expense
7.24M 7.29M 17.09M 24.25M
Interest Capitalized
- - - -
-
Pretax Income
(141.68M) (117.79M) (69.17M) (177.26M)
Pretax Income Growth
+11.51% +16.86% +41.28% -156.27%
Pretax Margin
-51.29% -39.80% -22.56% -56.97%
Income Tax
(4.28M) 356.00K 333.00K 716.00K
Income Tax - Current - Domestic
200.00K 144.00K 194.00K 181.00K
Income Tax - Current - Foreign
43.00K 204.00K 62.00K 454.00K
Income Tax - Deferred - Domestic
(4.52M) 9.00K 73.00K 83.00K
Income Tax - Deferred - Foreign
(1.00K) (1.00K) 4.00K (2.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(137.40M) (118.15M) (69.50M) (177.97M)
Minority Interest Expense
- - - -
-
Net Income
(137.40M) (118.15M) (69.50M) (177.97M)
Net Income Growth
+10.32% +14.01% +41.17% -156.07%
Net Margin Growth
-49.74% -39.92% -22.67% -57.20%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(137.40M) (118.15M) (69.50M) (177.97M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(137.40M) (118.15M) (69.50M) (177.97M)
EPS (Basic)
-2.5577 -2.0941 -1.1548 -2.5463
EPS (Basic) Growth
+20.71% +18.13% +44.85% -120.50%
Basic Shares Outstanding
53.72M 56.42M 60.18M 69.90M
EPS (Diluted)
-2.6271 -2.0941 -1.1548 -2.5463
EPS (Diluted) Growth
+18.56% +20.29% +44.85% -120.50%
Diluted Shares Outstanding
54.08M 56.42M 60.18M 69.90M
EBITDA
(71.36M) (40.55M) (13.32M) 9.80M
EBITDA Growth
+1.99% +43.18% +67.14% +173.53%
EBITDA Margin
-25.83% -13.70% -4.35% +3.15%

Snapshot

Average Recommendation HOLD Average Target Price 2.094
Number of Ratings 9 Current Quarters Estimate 0.029
FY Report Date 06 / 2026 Current Year's Estimate 0.112
Last Quarter’s Earnings 0.007 Median PE on CY Estimate N/A
Year Ago Earnings 0.18 Next Fiscal Year Estimate 0.139
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate 0.03 0.03 0.11 0.14
High Estimates 0.10 0.11 0.38 0.38
Low Estimate 0.00 -0.02 -0.02 0.00
Coefficient of Variance 122.86 157.99 127.14 96.40

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 0 0 0
HOLD 7 7 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Overweight

Insider Actions for Health Catalyst Inc - HCAT

Date Name Shares Transaction Value
Feb 20, 2026 Duncan p. Gallagher Director 132,023 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2025 Dan LeSueur Chief Operating Officer 211,041 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.15 per share 875,820.15

Health Catalyst Inc in the News